ACI-24.060
Early / Mid-stage
active
recruiting
CT.gov grounded
A vaccine-style Alzheimer's program that diversifies the monitor away from a monoclonal-antibody monoculture.
Program overview
- Mechanism
- anti-amyloid active immunotherapy
- Modality
- therapeutic vaccine
- Phase
- Early / Mid-stage
- Status
- active
- Recruitment
- recruiting
- Confidence
- medium
- Watch priority
- 3
- Last verified
- 20 Apr 2026
Sponsor and trial identifiers
- Sponsor
- AC Immune
- Trial IDs
- NCT05462106
ClinicalTrials.gov exact matches: NCT05462106
Regions and recruitment
United States
Spain
United Kingdom
Indication tags
Alzheimer's
amyloid vaccine
Milestones and catalysts
- Last milestone
- One of the cleaner active-immunotherapy shots in Alzheimer's that is still worth watching while antibodies dominate the headlines.
- Next expected catalyst
- Further safety and immunogenicity read-throughs in prodromal and established Alzheimer's cohorts.
Related pages
Disease hub
Alzheimer's disease hub
Disease-specific views with programs, mechanisms, and related context.
Related programs
Each card explains why it is here so you can read the overlap at a glance.
Approved / Late-stage
active
active, not recruiting
Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Further rollout, label evolution, and follow-up data.
- Last verified
- 20 Apr 2026
Approved / Late-stage
active
active, not recruiting
Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Additional post-approval data and uptake signals.
- Last verified
- 20 Apr 2026
Late-stage
active
active, not recruiting
A precision-style Alzheimer's program built around APOE4 biology rather than a broad undifferentiated patient pool.
- Mechanism
- anti-amyloid oligomer modulation
- Modality
- small molecule
- Next catalyst
- Long-term extension updates and any signal on APOE4-enriched positioning.
- Last verified
- 20 Apr 2026
Mid / Late-stage
active
active, not recruiting
Follow-on anti-amyloid program that could matter for the next wave of Alzheimer's competition.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Recruitment updates and larger efficacy or safety read-throughs.
- Last verified
- 20 Apr 2026
Recent program changes
ACI-24.060
Added to the monitor: ACI-24.060 · Alzheimer's disease · Early / Mid-stage.